Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

The stroke market is experiencing unprecedented growth, fueled by intense corporate investment and disruptive technologies ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

The advanced heart failure market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical companies such as ...

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, representing a potential paradigm shift if approved by the FDA, while highlighting ...

It's CeraVe-time to celebrate! CeraVe, the global skincare brand recommended by 80,000 dermatologists worldwide1, is celebrating a major milestone: 20 years of skin barrier authority, championing ...

In the rapidly evolving landscape of nuclear medicine, the integration of diagnostics and therapeutics - known as ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

Q2 2025 Earnings Call Transcript July 22, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $2.81, expectations were $2.77. Operator: Ladies and gentlemen, thank you for standing ...

DelveInsight’s, “Multiple Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ ...

Juvenile-adolescent rats produce ultrasonic vocalizations characteristic of a pleasant sensation in response to repeated ...